Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted ...

On Wednesday, 21 May 2025, Cytokinetics (NASDAQ:CYTK) participated in the RBC Capital Markets Global Healthcare Conference 2025, providing a comprehensive update on its drug development pipeline.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary ...

Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions. HEOR Analyses of Real-World Dat ...

Market forces rained on the parade of Cytokinetics, Incorporated (NASDAQ:CYTK) shareholders today, when the analysts downgraded their forecasts for this year. This report focused on revenue estimates, ...

Malik, M.D., Ph.D., Cytokinetics' Executive Vice President of Research & Development. "Importantly, the results from ...

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary Landscapes in ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

SOUTH SAN FRANCISCO, Calif., May 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM ...